103633-30-3

Basic information

• Product Name: 2-BENZYLOXYBENZYLBROMIDE
• Synonyms: Benzene, 1-(broMoMethyl)-2-(phenylMethoxy)-;1-(benzyloxyMethyl)-2-(broMoMethyl)benzene;2-BENZYLOXYBENZYLBROMIDE
• CAS NO: 103633-30-3
• Molecular Formula: C₁₄H₁₃BrO
• Molecular Weight: 277.16
• Product Categories: pharmacetical
• Mol File: 103633-30-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 40-42 °C
• Boiling Point: 354.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.361±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2-BENZYLOXYBENZYLBROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZYLOXYBENZYLBROMIDE(103633-30-3)
• EPA Substance Registry System: 2-BENZYLOXYBENZYLBROMIDE(103633-30-3)

Safety Data

• Hazardous Substances Data: 103633-30-3(Hazardous Substances Data)

Usage

General Description

2-Benzyl?oxybenzylbromide, also known as phenyl(phenylmethoxy)methyl bromide, is an organic compound and a type of organobromine compound. This reagent is used in the organic synthesis of other chemical compounds, particularly within the pharmaceutical industry. Its molecular formula is C14H13BrO2 and it appears as a solid substance under normal room settings. Due to its reactive nature, it should be handled with protective gear due to potential threats to skin, eyes or respiratory system if exposed.

Upstream product

• 100-39-0 benzyl bromide 
• 90-02-8 salicylaldehyde 
• 100-44-7 benzyl chloride 
• 5896-17-3 2-(phenylmethoxy)benzaldehyde 
• 89-95-2 2-methyl-benzyl alcohol 
• 90-01-7 salicylic alcohol 
• 3381-87-1 2-benzyloxybenzyl alcohol 

Downstream Products

• 212116-74-0 (Z)-2,3'-dibenzyloxy-4',5'-dimethoxystilbene 
• 212116-75-1 (E)-2,3'-dibenzyloxy-4',5'-dimethoxystilbene 
• 1224629-60-0 3-(o-benzyloxy)benzyl-1,5,5-trimethylimidazolidine-2,4-dione 
• 1209470-16-5 C₃₆H₃₂O₆ 
• 1209470-18-7 4',6'-bis[2-(benzyloxy)benzyloxy]-2'-hydroxychalcone 
• 1209470-19-8 7-[2-(benzyloxy)benzyloxy]-5-hydroxyflavanone 
• 106419-88-9 diethyl 2-(2-(benzyloxy)benzyl)malonate 
• 106419-92-5 2-[2-(benzyloxy)benzyl]-1,3-propanediol 

Relevant articles and documents

Solvent responsive catalyst improves NMR sensitivity: Via efficient magnetisation transfer

A bidentate iridium carbene complex, Ir(κC,O-L1)(COD), has been synthesised which contains a strongly electron donating carbene ligand that is functionalised by a cis-spanning phenolate group. This complex acts as a precursor to effective magne

Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists

Aim: Retinoic acid receptor-related orphan nuclear receptors (RORs) are orphan nuclear receptors that show constitutive activity in the absence of ligands. Among 3 subtypes of RORs, RORc is a promising therapeutic target for the treatment of Th17-mediated autoimmune diseases. Here, we report novel RORc inverse agonists discovered through structure-based drug design. Methods: Based on the structure of compound 8, a previously described agonist of RORa, a series of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives were designed and synthesized. The interaction between the compounds and RORc was detected at molecular level using AlphaScreen assay. The compounds were further examined in 293T cells transfected with RORc and luciferase reporter gene. Thermal stability shift assay was used to evaluate the effects of the compounds on protein stability. Results: A total of 27 derivatives were designed and synthesized. Among them, the compound 22b was identified as the most potent RORc inverse agonist. Its IC50 values were 2.39 μmol/L in AlphaScreen assay, and 0.82 μmol/L in inhibition of the cell-based luciferase reporter activity. Furthermore, the compound 22b displayed a 120-fold selectivity for RORc over other nuclear receptors. Moreover, a molecular docking study showed that the structure-activity relationship was consistent with the binding mode of compound 22b in RORc. Conclusion: 4-(4-(Benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives are promising candidates for the treatment of Th17-mediated autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Use of the cascade α-oxo-amidoalkylation/transposition/π-cationic cyclization of N-acyliminium ions in the synthesis of novel fused heterocyclic N,O-acetals

Tricyclic N,O-acetal scaffolds have been prepared easily in few steps starting from cheap reagents in moderate to good yields (40-68%) in which the α-hydroxy lactam intermediates constitute the key substrates. These cyclized products are the result of the